Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73438
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73438
Character Range: 24669–25828

73438              A DNA‑based multi‑gene panel test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:                                                                                                                                                                                                                                                                                                                                                                                                                                                  682.35
                     (a) to detect variants in at least EGFR, BRAF, KRAS and MET exon 14; and
                     (b) to determine access to specific therapies relevant to these variants listed on the Pharmaceutical Benefits Scheme (PBS); or
                     (c) to determine if the requirements relating to EGFR status for access to immunotherapies listed on the PBS are fulfilled; and
                     (d) not associated with a service to which item 73437, 73337, 73436 or 73351 applies